CAMBRIDGE, Mass., April 18,
2024 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced that it will host a live conference
call and webcast at 8:00 a.m. ET on
Thursday, May 2, 2024, to report its first quarter 2024
financial results and provide a corporate update.
To access the live conference call, please dial 833-470-1428
(domestic) or 404-975-4839 (international) and refer to conference
ID 186292. A webcast of the call will also be available under
"Events and Presentations" in the Investors & Media section of
the Blueprint Medicines website at
http://ir.blueprintmedicines.com/. The archived webcast will be
available on Blueprint Medicines' website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Blueprint Medicines
Blueprint Medicines is a fully integrated,
commercial-stage, global biopharmaceutical company that invents
life-changing medicines in two core, strategic areas of
allergy/inflammation and oncology/hematology. We pursue discovery,
development, and commercialization of therapies that potently and
selectively target known drivers of disease, with focused
investment in therapeutic areas where we can leverage our core
expertise and business infrastructure to bring scale to our
science. We are bringing AYVAKIT®/AYVAKYT®
(avapritinib) to people living with systemic mastocytosis (SM) in
the U.S. and Europe. Additionally, we have a
pipeline of research and development programs that range from early
science to advanced clinical trials in mast cell-mediated diseases,
including SM and chronic urticaria, and oncology including breast
cancer, and other solid tumors vulnerable to CDK2 inhibition. For
more information, visit www.BlueprintMedicines.com and
follow us on X (formerly Twitter; @BlueprintMeds)
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2024-financial-results-on-thursday-may-2-2024-302119817.html
SOURCE Blueprint Medicines Corporation